New hope for tough lymphoma: experimental drug JS203 enters human testing
NCT ID NCT05618327
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study is testing an experimental drug called JS203 in about 104 people with relapsed or refractory B-cell non-Hodgkin's lymphoma, a type of blood cancer. The main goals are to check the drug's safety, find the right dose, and see if it shows any signs of shrinking tumors. Participants receive the drug through an IV on a schedule that depends on the dose group they are assigned to.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
JS203 (an experimental drug for injection)
What this could lead to
If successful, this could lead to a new treatment option for patients with B-cell non-Hodgkin's lymphoma that has not responded to other therapies.
What could go wrong
This is an early Phase 1 trial with only 104 participants, so the drug may not prove effective or safe in larger studies. Side effects are unknown and could be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China